Spots Global Cancer Trial Database for previously treated myelodysplastic syndromes
Every month we try and update this database with for previously treated myelodysplastic syndromes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome | NCT00017550 | Myelodysplastic... | anti-thymocyte ... | 18 Years - 120 Years | Sanofi | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT00818649 | Leukemia Myelodysplastic... | bortezomib vorinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome | NCT00004208 | Myelodysplastic... | ATG + CSA Supportive care | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00003790 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry | - 21 Years | Children's Oncology Group | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | NCT00003415 | Leukemia Myelodysplastic... | amifostine trih... topotecan hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | NCT00003997 | Leukemia Myelodysplastic... | irofulven | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01707004 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... | decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom... | 18 Years - 75 Years | University of Wisconsin, Madison | |
| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | NCT00352001 | Leukemia Myelodysplastic... | azacitidine lenalidomide | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Paricalcitol in Treating Patients With Myelodysplastic Syndrome | NCT00064376 | Leukemia Myelodysplastic... | paricalcitol | 25 Years - 100 Years | Cedars-Sinai Medical Center | |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | NCT01235572 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult... | standard follow... medical chart r... quality-of-life... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Belinostat in Treating Patients With Myelodysplastic Syndromes | NCT00357162 | de Novo Myelody... Previously Trea... Secondary Myelo... | belinostat | 18 Years - | National Cancer Institute (NCI) | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Empirical Versus Preemptive Antifungal Therapy | NCT01288378 | Fungal Infectio... Leukemia Myelodysplastic... | caspofungin ace... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | NCT00118196 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - 120 Years | Medical University of South Carolina | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00119366 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo... | iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom... | 16 Years - 50 Years | Fred Hutchinson Cancer Center | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | NCT00356928 | Leukemia Myelodysplastic... | Cyclophosphamid... Donor T cells | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | NCT00093743 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea... | fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m... | - | Fred Hutchinson Cancer Center | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00003959 | Leukemia Myelodysplastic... | ras peptide can... sargramostim | 17 Years - | Memorial Sloan Kettering Cancer Center | |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | NCT01564277 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult... | rasburicase allopurinol | 18 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | NCT00093743 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea... | fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m... | - | Fred Hutchinson Cancer Center | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | NCT00002547 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ... | - 60 Years | Barbara Ann Karmanos Cancer Institute | |
| Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant | NCT00898118 | Leukemia Myelodysplastic... | polymerase chai... flow cytometry laboratory biom... allogeneic hema... | - 17 Years | National Cancer Institute (NCI) | |
| Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | NCT00618696 | Leukemia Myelodysplastic... | anti-CD45 monoc... yttrium Y 90 an... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00397579 | Leukemia Myelodysplastic... Blastic Plasmac... | DT388IL3 | 18 Years - | University of Texas Southwestern Medical Center | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer | NCT00126477 | Leukemia Lymphoma Myelodysplastic... Quality of Life | cognitive asses... management of t... psychosocial as... quality-of-life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | NCT00352001 | Leukemia Myelodysplastic... | azacitidine lenalidomide | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | NCT01235572 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Previously Trea... Recurrent Adult... | standard follow... medical chart r... quality-of-life... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | NCT00005942 | Chronic Myelomo... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... | liposomal dauno... semaxanib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | NCT00544466 | Leukemia Myelodysplastic... | fludarabine pho... melphalan allogeneic hema... intensity-modul... | 7 Years - | City of Hope Medical Center | |
| Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
| Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00028899 | Leukemia Myelodysplastic... | asparaginase cytarabine gemtuzumab ozog... mitoxantrone hy... | - 21 Years | Children's Oncology Group | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00475150 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01707004 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... | decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom... | 18 Years - 75 Years | University of Wisconsin, Madison | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00003048 | Myelodysplastic... | Amifostine Trih... | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
